Calcium Channel Blocker in DM1: Can amlodipine help myotonic dystrophy type 1
Official title: Calcium Channel Blocker in Myotonic Dystrophy Type 1 (CAP DM1)
Funded at University of Rochester · NIH-11444061 · Data updated 2026-11-12
This study tests whether the calcium‑channel blocker amlodipine can improve symptoms and survival in myotonic dystrophy type 1 (DM1).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $1,335,086 |
| NIH project number | 1R01FD008510-01A1 |
| Project ID | NIH-11444061 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with DM1 or related muscle weakness disorders who could participate through future clinical trials.
✕Less likely to help
Patients without DM1 or with conditions unrelated to calcium channel pathways may not benefit.
What this research studies
DM1 causes muscle weakness, myotonia, heart and breathing problems, and currently has no FDA‑approved therapies. The project explores how a drug that blocks calcium entry might reduce harmful changes in muscle cells caused by the disease. Researchers will use DM1 models to see if amlodipine can improve muscle strength, myotonia, and survival, and to understand the underlying biology. If successful, findings could guide future trials in people with DM1.
Why it matters
Potential benefit: If the approach works, it could lead to a new treatment strategy to ease DM1 symptoms and potentially extend lifespan.
How similar studies have gone: Previous animal studies showed improved survival and symptoms with calcium channel blockade in DM1 models, but human data are needed.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Hamel, Johanna I — University of Rochester
- Study coordinator: Hamel, Johanna I
Related research
Other NIH-funded projects on the same topics.
-
New small molecule therapeutics to help myotonic dystrophy
A new NIH-funded project tests specially designed small molecules to lower harmful RNA activity in myotonic dystrophy and related diseases, aiming to reduce disease-driving RNA effects.
-
Mechanisms of muscle disease in myotonic dystrophy type 1
This project looks at why skeletal muscles weaken and waste away in adults with myotonic dystrophy type 1 and aims to uncover the underlying molecular causes.
-
Extracellular vesicle biomarkers to monitor DM1 using urine and blood samples
A study looking for easy, noninvasive biomarkers in urine and blood to track disease activity in people with myotonic dystrophy type 1.
-
Preparing therapies for DM1 across ages, with a focus on children
A broad, patient-focused effort to bring promising DM1 therapies to both children and adults by enriching trial readiness, biomarkers, and natural history data.
-
Biological factors that drive variability in myotonic dystrophy
This grant explores why myotonic dystrophy can look very different from person to person by studying its genetic changes and how they affect muscle in adults.
-
Identifying RNA Splicing and Gene Expression Changes in congenital myotonic dystrophy
This grant looks at how RNA changes contribute to congenital myotonic dystrophy to understand why symptoms change as children grow.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.